Retinal Vein Occlusion Treatment Market 2030: Innovations Revolutionizing RVO Therapy
Global Retinal Vein Occlusion Treatment Market Overview The global retinal vein occlusion (RVO) treatment market was valued at USD 2.48 billion in 2022 and is projected to reach USD 4.18 billion by 2030, growing at a CAGR of 6.92% from 2023 to 2030. The market growth is primarily driven by an increasing geriatric population, the rising prevalence of retinal diseases, and growing awareness of eye health and related disorders. In addition, expanding R&D activities, a strong drug development pipeline, and increasing regulatory approvals for RVO treatments are key factors expected to fuel market expansion over the coming years. For instance, in August 2022, Kodiak Sciences Inc. reported positive outcomes from the BEACON Phase 3 trial evaluating tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema and vision loss due to RVO. Such advancements highlight the growing industry focus on developing novel, long-acting therapies, offering promising opportunities for mark...